'Nonfatal mi' diaporamas de présentation

C. Michael Gibson, M.S., M.D.

919 views • 69 slides

Treatment of Hypertension in the Elderly: A Major Challenge

Treatment of Hypertension in the Elderly: A Major Challenge. Thomas G Pickering MD, D Phil Behavioral Cardiovascular Health and Hypertension Program Columbia Presbyterian Hospital. Treating older adults: Updates and Practical Approaches. Risks associated with high BP JNC 7 Guidelines

1.24k views • 48 slides

Role of RAAS Modulation: Recent Clinical Trials

VBWG. Role of RAAS Modulation: Recent Clinical Trials. CAD Diabetes ACEIs and ARBs. VBWG. Benefit of ACE inhibition in CAD. SOLVD SAVE AIRE TRACE. Post-MI, HF, LVEF <40%. HOPE. SOLVD (prev). High risk. EUROPA. All CAD patients. Bertrand ME . Curr Med Res Opin. 2004;20:1559-69.

546 views • 44 slides

CV Risk Reduction, Diabetes Prevention, and TZDs

CV Risk Reduction, Diabetes Prevention, and TZDs. UKPDS 34: Intensive glucose control and CV protection. n = 1704 overweight, with diabetes; n = 342 metformin group. Aggregate endpoints. Favors metformin or intensive. Favors usual care. P*. All-cause mortality Metformin Intensive

650 views • 43 slides

CV Risk Reduction, Diabetes Prevention, and TZDs

CV Risk Reduction, Diabetes Prevention, and TZDs. UKPDS 34: Intensive glucose control and CV protection. n = 1704 overweight, with diabetes; n = 342 metformin group. Aggregate endpoints. Favors metformin or intensive. Favors usual care. P*. All-cause mortality Metformin Intensive

435 views • 43 slides

Chenxiong (Charles) Le, Ph.D. OBI/OB/OPaSS/CDER, FDA Cardiovascular and Renal Drugs

505 views • 27 slides

Comparative effectiveness reviews: methodological observations

Comparative effectiveness reviews: methodological observations. David B. Matchar, MD Professor of Medicine and Director, Center for Clinical Health Policy Research Duke University Medical Center. I. Drug-Eluting vs. Bare Metal Stents: Results from a Practice-Based Registry.

368 views • 26 slides

Conflict of interest Kim Fox receives honoraria, fees, travel expenses from Servier

S tudy assess I n G the morbidity-mortality be N efits of the I f inhibitor ivabradine in patients with coronar Y artery d isease without heart failure. Conflict of interest Kim Fox receives honoraria, fees, travel expenses from Servier. Study organisation.

311 views • 20 slides

Conflict of interest Kim Fox receives honoraria, fees, travel expenses from Servier

S tudy assess I n G the morbidity-mortality be N efits of the I f inhibitor ivabradine in patients with coronar Y artery d isease without heart failure. Conflict of interest Kim Fox receives honoraria, fees, travel expenses from Servier. Study organisation.

344 views • 20 slides

Atorvastatin Versus Revascularization Treatments (AVERT) Trial

AVERT Trial. Atorvastatin Versus Revascularization Treatments (AVERT) Trial. Presented at The American Heart Association Scientific Sessions 1998 Presented by Dr. Bertram Pitt. AVERT Trial: Background.

494 views • 17 slides

Design and baseline characteristics

Design and baseline characteristics. Trial hypothesis. SIGNIFY is assessing whether heart rate reduction using ivabradine improves cardiovascular mortality and morbidity in patients with stable CAD, without clinical heart failure. Fox K et al. Am Heart J. 2013;166(4):654-661.

250 views • 15 slides

ExTRACT-TIMI 25 : New Data

ExTRACT-TIMI 25 : New Data. Elliott M. Antman, MD. This presentation reflects the views of the presenter and does not necessarily reflect the views of the American College of Cardiology Content Distributed by Cardiosource. Disclosure.

273 views • 14 slides

Invasive vs. Selective strategy NSTEMI

Invasive vs. Selective strategy NSTEMI. Objective: To determine whether a routine invasive (RI) strategy reduces the long-term frequency of cardiovascular death or nonfatal MI using a meta analysis of individual data from FRISC II , ICTUS an RITA-3 trials.

168 views • 4 slides